[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Math 408 Group Project Proposal",
    "section": "",
    "text": "Miles O’Brien  Johnathan Harrell  Jasmine Wright  Kamaran Francis  Junxi (Steven) Li  Cameron Garcia"
  },
  {
    "objectID": "index.html#purpose",
    "href": "index.html#purpose",
    "title": "Math 408 Group Project Proposal",
    "section": "Purpose:",
    "text": "Purpose:\nBiomarkers are important because it may be possible for scientists to use them to detect, classify, and measure the type of cancer present in a patient. Research is ongoing to support whether or not biomarkers alone are enough to determine cancer types and potential treatments in patients. Patient data can aid in discovering the relationship between specific biomarkers, such as genes that encode proteins. These biomarkers can play an important role in discovering how treatments can be applied to specific cancer types. Our work continues with results obtained in a Master’s thesis by Sheena Mogan titled “Biomarker Discovery by Semi-Supervised Non-Negative Matrix Factorization”. Our goal is to apply Non-Negative Canonical Polyadic Decomposition (NNCPD) to the datasets used in her research and compare our results to her findings. Furthermore, we will confirm the links between the genetic information and cancer types found by NNCPD in the datasets in comparison to the results that have been confirmed in the peer-reviewed publications. We chose NNCPD because of its ability to process multi-omics data tensors, unlike other algorithms limited by their inability to analyze data in more than two dimensions. We hope this method of analyzing genetic oncological data will provide oncologists with a wider lens regarding patient cancer types and possible outcomes of treatment."
  },
  {
    "objectID": "index.html#data",
    "href": "index.html#data",
    "title": "Math 408 Group Project Proposal",
    "section": "Data:",
    "text": "Data:\nThe data set we used is from the Cancer Cell Line Encyclopedia and was provided by N. Fujita. It includes 24 cancer types, as well as five types of genetic information and variables for 1054 patients. We use this information to train the algorithm and identify clusters in the biomarker information that ultimately helps us assign a specific cancer type with certain confidence to each subject."
  },
  {
    "objectID": "index.html#variables",
    "href": "index.html#variables",
    "title": "Math 408 Group Project Proposal",
    "section": "Variables:",
    "text": "Variables:\nThe variables used in the CCLE data set are listed below, along with their dimensionality and data type. These variables are:  - Compound Sensitivity  - Mutation  - Copy Number Amplification  - Copy Number Loss  - mRNA Expression  - Tumor Type"
  },
  {
    "objectID": "index.html#end-product",
    "href": "index.html#end-product",
    "title": "Math 408 Group Project Proposal",
    "section": "End Product:",
    "text": "End Product:\nWe hope to produce a topic model algorithm that can mirror Sheena Mogan’s and Naoya Fujita’s results that showed Biomarkers can be used to identify Cancer drugs that are able to treat certain types of cancer that have been shown through clinical studies to be difficult to treat either because they return after being treated or metastasis easily in certain parts of the body. Our results eliminate the need to analyze each data frame separately by stacking them into a single tensor before applying Non-negative Canonical Polyadic Decomposition. \\[\nLatex format section\n\\]\n\n# TODO\n# Figure out how to list modules in index in the order you decide rather than just in alphabetical order (which is the default)"
  },
  {
    "objectID": "Clinical Analysis of SSNMF.html",
    "href": "Clinical Analysis of SSNMF.html",
    "title": "Clinical Analysis of SSNMF",
    "section": "",
    "text": "Through careful analysis of our derived data and published clinical trial results, we observed associations between drug sensitivity and the relevance of cancer biomarkers produced in the comodules. Given cancer’s aggressive and variable response across patients, identifying these biomarkers is crucial for informing treatment decisions by physicians. By refining a broader dataset of cell lines, physicians can make more informed prognostic plans that are tailored to each individual cancer type. Given the randomness of genetic variations in cancers across and within organs, correlations between biomarkers and drug sensitivity offers broader insights into how cancer cells are likely to respond to treatment.\n\n\n\nIn comodule 1, a strong correlation between the use of cancer biomarkers TP53 and the RAB25 mRNA expression is observed. Both p53 and RAB 25 have served as prognostic biomarkers in literature, with p53 being one of the most common cancer mutations (1,2). Moreover, all drugs in this comodule have mechanisms of action involved in halting the progression of DNA replication and cell communication from the chromosome to the cytoplasm of the cell. (3,4,5,6,7).\n\n\n \n\n16 mutations were observed in comodule 2. All mutations were used in literature as biomarkers for diagnosis, treatment sensitivity, tumor progression and prognosis (7). Moreover these mutations encode proteins which will serve in DNA replication and cell communication. Saracatinib halts communication in the cell, while topotecan halts dna replication in the chromosome. Both drugs have been used in literature as a second line treatment in cancer, especially in lung cancer (3,9).\n\nComodule 21 also contains mutations which give insight to other aspects of a cancer profile of a patient, such as cancer risk, tumor burden, and likelihood of malignancy (10). Both drugs in this comodule have been identified as topoisomerase inhibitors which inhibit the initiation of DNA replication (11,12). These drugs may be used to halt the replication of mutated sequences of RNA present in cancers.\nIn comodule 22, data for mRNA biomarkers along with two mutations are observed. These mRNA biomarkers give indication into diagnosis of cancer severity, drug resistance and sensitivity (13). Furthermore, mutations in the KRAS and Tp53 gene are observed. The mutation in the TP53 gene will inhibit cell death, while a mutation in the kras gene will disrupt proper cell signaling (14,15). This comodule gives insight that is useful for targeted therapy in cancer. All drugs in this comodule also serve to halt all DNA replication and communication in the cell. (3,4,5,7)\nIn comodule 23, a mutation along with a copy number loss is observed. The mutation of TTN is used as a biomarkers for tumor burden analysis (16). Two genes are shown in this commodule as having copy number losses. They involve olfactory genes OR4M2 and OR4N4. Both of these are biomarkers explain heritable risk in cancer (17). In sum, commodule 23 provides insight into tumor burden and hereditary risk.\nIn comodule 35, copy number loss data may provide insight to sex-linked cancers, treatment progress, and cancer risk in patients(18,19). In this table, the drug TAE684 inhibits cell communication through inhibiting kinase proteins (6).\nCommodule 3 provides information on breast cancer type, and the drug topotecan. In clinical trials, this drug has been used successfully in reducing the amount of cancer cells in breast tissue after first line treatment has failed (21). Comodule 6 referenses the represents lung cancer specifically. In literature, mutations of TTN are used as biomarkers for mutation burden(16), while CSMD3 is stated to be the second most commonly mutated gene in lung cancer (22). Topotecan is approved by the FDA as a second line treatment for lung cancer (23)\nLastly, comodule 13 provides data for hematopoietic and lymphoid tissue cancers. All drugs in this comodule have been used with some success in clinical trials to treat blood and lymphatic cancers. (6,24,25,26)\nIn summary, these biomarkers provide a treating oncologist with the necessary insights to personalize treatment approaches and improve therapeutic outcomes of patients.\n\n\n\nXiong, J., Li, S., & Zeng, X. (2017). High Rab25 expression associates with Ki67/TP53/CD133/VEGFR expression predicts poor prognosis in gastric cancer. International journal of clinical and experimental pathology, 10(7), 7792–7800.\nSharma, S., Carlson, S., Gregory-Flores, A., Hinojo-Perez, A., Olson, A., & Thippeswamy, T. (2021). Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy. Neurobiology of Disease, 156, 105410. https://doi.org/10.1016/j.nbd.2021.105410\nRamos, R., & Vale, N. (2024). Dual drug repurposing: The example of saracatinib. International Journal of Molecular Sciences, 25(8), 4565. https://doi.org/10.3390/ijms25084565\nOpdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M. (2012). Lapatinib for advanced or metastatic breast cancer. The Oncologist, 17(4), 536–542. https://doi.org/10.1634/theoncologist.2011-0461\nWeber, J. S., Levit, L. A., Adamson, P. C., Bruinooge, S. S., Burris, H. A., Carducci, M. A., Gönen, M., Keefe, S. M., Waterhouse, D. M., Weiner, S. L., & Schuchter, L. M. (2025). The critical role of phase I trials in cancer research and treatment. Journal of Clinical Oncology, 43(5), 123-134. https://doi.org/10.1200/JCO.24.01034\nGalkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., & Gray, N. S. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America, 104(1), 270–275. https://doi.org/10.1073/pnas.0609412103\nTakahashi, N., Hao, Z., Villaruz, L. C., Zhang, J., Ruiz, J., Petty, W. J., Mamdani, H., Riess, J. W., Nieva, J., Pachecho, J. M., Fuld, A. D., Shum, E., Chauhan, A., Nichols, S., Shimellis, H., McGlone, J., Sciuto, L., Pinkiert, D., Graham, C., Shelat, M., … Thomas, A. (2023). Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA oncology, 9(12), 1669–1677. https://doi.org/10.1001/jamaoncol.2023.4025\nAsaf, S., Maqsood, F., Jalil, J., Sarfraz, Z., Sarfraz, A., Mustafa, S., & Cherrez Ojeda, I. (2023). Lipocalin 2—not only a biomarker: A study of current literature and systematic findings of ongoing clinical trials. Immunologic Research, 71(3), 287–313. https://doi.org/10.1007/s12026-022-09352-2\nPetrelli, F., Ghidini, A., & Luciani, A. (2021). Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies. Molecular and Clinical Oncology, 15(4), 218. https://doi.org/10.3892/mco.2021.2383\nBazzichetto, C., Conciatori, F., Pallocca, M., Falcone, I., Fanciulli, M., Cognetti, F., Milella, M., & Ciuffreda, L. (2019). PTEN as a prognostic/predictive biomarker in cancer: An unfulfilled promise? Cancers, 11(4), 435. https://doi.org/10.3390/cancers11040435\nKollmannsberger, C., Mross, K., Jakob, A., Kanz, L., & Bokemeyer, C. (1999). Topotecan—a novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56(1), 1–12. https://doi.org/10.1159/000011923\nHasinoff, B. B., Wu, X., Nitiss, J. L., Kanagasabai, R., & Yalowich, J. C. (2012). The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochemical Pharmacology, 84(12), 1617–1626. https://doi.org/10.1016/j.bcp.2012.09.023\nMorgenstern-Kaplan, D., Kareff, S. A., Trabolsi, A., Rodriguez, E., Krause, H., Ribeiro, J. R., Tan, H., Antonarakis, E. S., Lou, E., Nagasaka, M., Algaze, S., Lenz, H.-J., Liu, S. V., Halmos, B., Hoon, D. S. B., Seeber, A., Ma, P. C., El-Deiry, W. S., Vanderwalde, A. M., & Lopes, G. (2024). Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The Oncologist, 29(11), e1480–e1491. https://doi.org/10.1093/oncolo/oyae168\nMcBride, O. W., Merry, D., & Givol, D. (1986). The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proceedings of the National Academy of Sciences of the United States of America, 83(1), 130–134. https://doi.org/10.1073/pnas.83.1.130\nMasjedi, S., Zwiebel, L. J., & Giorgio, T. D. (2019). Olfactory receptor gene abundance in invasive breast carcinoma. Scientific Reports, 9(1), 13736. https://doi.org/10.1038/s41598-019-50085-4\nChen, J., Wen, Y., Su, H., Yu, X., Hong, R., Chen, C., & Su, C. (2022). Deciphering prognostic value of TTN and its correlation with immune infiltration in lung adenocarcinoma. Frontiers in Oncology, 12, 877878. https://doi.org/10.3389/fonc.2022.877878\nMasjedi, S., Zwiebel, L. J., & Giorgio, T. D. (2019). Olfactory receptor gene abundance in invasive breast carcinoma. Scientific Reports, 9(1), 13736. https://doi.org/10.1038/s41598-019-50085-4\nMolnar, C., Heinen, J. P., Reina, J., Llamazares, S., Palumbo, E., Breschi, A., Gay, M., Villarreal, L., Vilaseca, M., Pollarolo, G., & González, C. (2019). The histone code reader PHD finger protein 7 controls sex-linked disparities in gene expression and malignancy in Drosophila. Science Advances, 5(8), eaaw7965. https://doi.org/10.1126/sciadv.aaw7965\nChaiyawat, P., Phanphaisarn, A., Sirikaew, N., Klangjorhor, J., Thepbundit, V., Teeyakasem, P., Phinyo, P., Pruksakorn, D., & Settakorn, J. (2021). IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma. Scientific Reports, 11(1), 10887. https://doi.org/10.1038/s41598-021-90456-4\nGalkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., & Choi, S. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America, 104(1), 270–275. https://doi.org/10.1073/pnas.0609412103\nJaeckle, K. A., Dixon, J. G., Anderson, S. K., Moreno-Aspitia, A., Colon-Otero, G., Hebenstreit, K., Patel, T. A., Reddy, S. L., & Perez, E. A. (2020). Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Medicine, 9(21), 7935–7942. https://doi.org/10.1002/cam4.3422\nLiu, P., Morrison, C., Wang, L., Xiong, D., Vedell, P., Cui, P., Hua, X., Ding, F., Lu, Y., James, M., Ebben, J. D., Xu, H., & Adjei, A. A. (2012). Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis, 33(7), 1270–1276. https://doi.org/10.1093/carcin/bgs148\nU.S. Food and Drug Administration. (1998). Hycamtin (topotecan hydrochloride) injection: Drug approval package. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20671s004.cfm\nChristensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics, 6(12), 3314–3322. https://doi.org/10.1158/1535-7163.MCT-07-0365\nGambacorti-Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, M. C., Guerra, L., Antolini, L., & Piazza, R. G. (2014). Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase–positive lymphoma patients. Journal of the National Cancer Institute, 106(2), djt378. https://doi.org/10.1093/jnci/djt378\nSchäfer, N., Gielen, G. H., Kebir, S., Wieland, A., Till, A., Mack, F., Schaub, C., Tzaridis, T., Reinartz, R., Niessen, M., Fimmers, R., Simon, M., Coch, C., Fuhrmann, C., Herrlinger, U., Scheffler, B., & Glas, M. (2016). Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. Journal of Cancer Research and Clinical Oncology, 142(7), 1581–1589. https://doi.org/10.1007/s00432-016-2161-0"
  },
  {
    "objectID": "Clinical Analysis of SSNMF.html#bibliography",
    "href": "Clinical Analysis of SSNMF.html#bibliography",
    "title": "Clinical Analysis of SSNMF",
    "section": "",
    "text": "Xiong, J., Li, S., & Zeng, X. (2017). High Rab25 expression associates with Ki67/TP53/CD133/VEGFR expression predicts poor prognosis in gastric cancer. International journal of clinical and experimental pathology, 10(7), 7792–7800.\nSharma, S., Carlson, S., Gregory-Flores, A., Hinojo-Perez, A., Olson, A., & Thippeswamy, T. (2021). Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy. Neurobiology of Disease, 156, 105410. https://doi.org/10.1016/j.nbd.2021.105410\nRamos, R., & Vale, N. (2024). Dual drug repurposing: The example of saracatinib. International Journal of Molecular Sciences, 25(8), 4565. https://doi.org/10.3390/ijms25084565\nOpdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M. (2012). Lapatinib for advanced or metastatic breast cancer. The Oncologist, 17(4), 536–542. https://doi.org/10.1634/theoncologist.2011-0461\nWeber, J. S., Levit, L. A., Adamson, P. C., Bruinooge, S. S., Burris, H. A., Carducci, M. A., Gönen, M., Keefe, S. M., Waterhouse, D. M., Weiner, S. L., & Schuchter, L. M. (2025). The critical role of phase I trials in cancer research and treatment. Journal of Clinical Oncology, 43(5), 123-134. https://doi.org/10.1200/JCO.24.01034\nGalkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., & Gray, N. S. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America, 104(1), 270–275. https://doi.org/10.1073/pnas.0609412103\nTakahashi, N., Hao, Z., Villaruz, L. C., Zhang, J., Ruiz, J., Petty, W. J., Mamdani, H., Riess, J. W., Nieva, J., Pachecho, J. M., Fuld, A. D., Shum, E., Chauhan, A., Nichols, S., Shimellis, H., McGlone, J., Sciuto, L., Pinkiert, D., Graham, C., Shelat, M., … Thomas, A. (2023). Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA oncology, 9(12), 1669–1677. https://doi.org/10.1001/jamaoncol.2023.4025\nAsaf, S., Maqsood, F., Jalil, J., Sarfraz, Z., Sarfraz, A., Mustafa, S., & Cherrez Ojeda, I. (2023). Lipocalin 2—not only a biomarker: A study of current literature and systematic findings of ongoing clinical trials. Immunologic Research, 71(3), 287–313. https://doi.org/10.1007/s12026-022-09352-2\nPetrelli, F., Ghidini, A., & Luciani, A. (2021). Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies. Molecular and Clinical Oncology, 15(4), 218. https://doi.org/10.3892/mco.2021.2383\nBazzichetto, C., Conciatori, F., Pallocca, M., Falcone, I., Fanciulli, M., Cognetti, F., Milella, M., & Ciuffreda, L. (2019). PTEN as a prognostic/predictive biomarker in cancer: An unfulfilled promise? Cancers, 11(4), 435. https://doi.org/10.3390/cancers11040435\nKollmannsberger, C., Mross, K., Jakob, A., Kanz, L., & Bokemeyer, C. (1999). Topotecan—a novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56(1), 1–12. https://doi.org/10.1159/000011923\nHasinoff, B. B., Wu, X., Nitiss, J. L., Kanagasabai, R., & Yalowich, J. C. (2012). The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochemical Pharmacology, 84(12), 1617–1626. https://doi.org/10.1016/j.bcp.2012.09.023\nMorgenstern-Kaplan, D., Kareff, S. A., Trabolsi, A., Rodriguez, E., Krause, H., Ribeiro, J. R., Tan, H., Antonarakis, E. S., Lou, E., Nagasaka, M., Algaze, S., Lenz, H.-J., Liu, S. V., Halmos, B., Hoon, D. S. B., Seeber, A., Ma, P. C., El-Deiry, W. S., Vanderwalde, A. M., & Lopes, G. (2024). Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. The Oncologist, 29(11), e1480–e1491. https://doi.org/10.1093/oncolo/oyae168\nMcBride, O. W., Merry, D., & Givol, D. (1986). The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proceedings of the National Academy of Sciences of the United States of America, 83(1), 130–134. https://doi.org/10.1073/pnas.83.1.130\nMasjedi, S., Zwiebel, L. J., & Giorgio, T. D. (2019). Olfactory receptor gene abundance in invasive breast carcinoma. Scientific Reports, 9(1), 13736. https://doi.org/10.1038/s41598-019-50085-4\nChen, J., Wen, Y., Su, H., Yu, X., Hong, R., Chen, C., & Su, C. (2022). Deciphering prognostic value of TTN and its correlation with immune infiltration in lung adenocarcinoma. Frontiers in Oncology, 12, 877878. https://doi.org/10.3389/fonc.2022.877878\nMasjedi, S., Zwiebel, L. J., & Giorgio, T. D. (2019). Olfactory receptor gene abundance in invasive breast carcinoma. Scientific Reports, 9(1), 13736. https://doi.org/10.1038/s41598-019-50085-4\nMolnar, C., Heinen, J. P., Reina, J., Llamazares, S., Palumbo, E., Breschi, A., Gay, M., Villarreal, L., Vilaseca, M., Pollarolo, G., & González, C. (2019). The histone code reader PHD finger protein 7 controls sex-linked disparities in gene expression and malignancy in Drosophila. Science Advances, 5(8), eaaw7965. https://doi.org/10.1126/sciadv.aaw7965\nChaiyawat, P., Phanphaisarn, A., Sirikaew, N., Klangjorhor, J., Thepbundit, V., Teeyakasem, P., Phinyo, P., Pruksakorn, D., & Settakorn, J. (2021). IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma. Scientific Reports, 11(1), 10887. https://doi.org/10.1038/s41598-021-90456-4\nGalkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., & Choi, S. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America, 104(1), 270–275. https://doi.org/10.1073/pnas.0609412103\nJaeckle, K. A., Dixon, J. G., Anderson, S. K., Moreno-Aspitia, A., Colon-Otero, G., Hebenstreit, K., Patel, T. A., Reddy, S. L., & Perez, E. A. (2020). Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Medicine, 9(21), 7935–7942. https://doi.org/10.1002/cam4.3422\nLiu, P., Morrison, C., Wang, L., Xiong, D., Vedell, P., Cui, P., Hua, X., Ding, F., Lu, Y., James, M., Ebben, J. D., Xu, H., & Adjei, A. A. (2012). Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis, 33(7), 1270–1276. https://doi.org/10.1093/carcin/bgs148\nU.S. Food and Drug Administration. (1998). Hycamtin (topotecan hydrochloride) injection: Drug approval package. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20671s004.cfm\nChristensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular Cancer Therapeutics, 6(12), 3314–3322. https://doi.org/10.1158/1535-7163.MCT-07-0365\nGambacorti-Passerini, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., Messa, M. C., Guerra, L., Antolini, L., & Piazza, R. G. (2014). Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase–positive lymphoma patients. Journal of the National Cancer Institute, 106(2), djt378. https://doi.org/10.1093/jnci/djt378\nSchäfer, N., Gielen, G. H., Kebir, S., Wieland, A., Till, A., Mack, F., Schaub, C., Tzaridis, T., Reinartz, R., Niessen, M., Fimmers, R., Simon, M., Coch, C., Fuhrmann, C., Herrlinger, U., Scheffler, B., & Glas, M. (2016). Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. Journal of Cancer Research and Clinical Oncology, 142(7), 1581–1589. https://doi.org/10.1007/s00432-016-2161-0"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site\n\n1 + 1\n\n[1] 2"
  }
]